Update on new therapies with immune checkpoint inhibitors

Clinical Journal of Oncology Nursing

Volumn 20, Issue 4, 2016, Pages 405-410

  Peterson, Jennifer J ^a   Steele Moses, Susan K ^b  

^a CANCER TREATMENT CENTERS OF AMERICA   (United States)

^b Lake College   (United States)

Author keywords

CTLA 4; Immune checkpoint; Immunotherapy; PD 1; PD L1

Indexed keywords

MONOCLONAL ANTIBODY;

ADULT; ADVERSE DRUG REACTION; AGED; FEMALE; GENE; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MALE; MIDDLE AGED; NEOPLASMS; PROCEDURES; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GENES, CDC; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; NEOPLASMS; UNITED STATES;

EID: 84979073987     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/16.CJON.405-410     Document Type: Review

References (31)

1. American Cancer Society. (2015). What is cancer immunotherapy? Retrieved from http://www.cancer.org/treatment/treatmentsandsideeffects/treatmenttypes/immunotherapy/immunotherapy-what-is-immunotherapy
2. Bisanz, A. (2011). Diarrhea and its multiple causes [Video transcript]. Retrieved from http://www.mdanderson.org/transcripts/POE-Diarrhea-Multiple-Causes-Bisanz.htm
3. Bristol-Myers Squibb. (2015). Yervoy® (ipilimumab) [Package insert]. Retrieved from http://packageinserts.bms.com/pi/pi_yervoy.pdf
4. Bristol-Myers Squibb. (2016). Opdivo® (nivolumab) [Package insert]. Retrieved from http://packageinserts.bms.com/pi/pi_opdivo.pdf
5. ClinicalTrials.gov. (2015a). A study to compare BMS-936558 to the physician’s choice of either dacarbazine or carboplatin and paclitaxel in advanced melanoma patients that have progressed following anti-CTLA-4 therapy (CheckMate 037). Retrieved from https://www.clinicaltrials.gov/ct2/show/NCT01721746
6. ClinicalTrials.gov. (2015b). Study of BMS-936558 (nivolumab) compared to docetaxel in previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC) (CheckMate 017). Retrieved from https://clinicaltrials.gov/ct2/show/NCT01642004
7. ClinicalTrials.gov. (2015c). Study of nivolumab (BMS-936558) in patients with advanced or metastatic squamous cell nonsmallcell lung cancer who have received at least 2 prior systemic regimens. Retrieved from https://www.clinicaltrials.gov/ct2/show/results/NCT01721759?term=NCT01721759
8. ClinicalTrials.gov. (2015d). Study of pembrolizumab (MK- 3475) versus chemotherapy in participants with advanced melanoma (P08719/KEYNOTE-002). Retrieved from https://clinicaltrials.gov/ct2/show/NCT01704287
9. DuPage, M., Mazumdar, C., Schmidt, L.M., Cheung, A.F., & Jacks, T. (2012). Expression of tumour-specific antigens underlies cancer immunoediting. Nature, 482, 405–409. doi:10.1038/nature10803
10. Elgert, K.D. (2009). Immunology: Understanding the immune system (2nd ed.). Hoboken, NJ: John Wiley and Sons.
11. Giaccone, G., & Soria, J. (Eds.). (2008). Targeted therapies in oncology (2nd ed.). Boca Raton, FL: CRC Press.
12. Hanahan, D., & Weinberg, R.A. (2011). Hallmarks of cancer: The next generation. Cell, 144, 646–674.
13. Ito, F., & Chang, A.E. (2013). Cancer immunotherapy: Current status and future directions. Surgical Oncology Clinics of North America, 22, 765–783
14. Kannan, R., Madden, K., & Andrews, S. (2014). Primer on immuno-oncology and immune response. Clinical Journal of Oncology Nursing, 18, 311–317. doi:10.1188/14.CJON.311-317
15. Lartigue, J. (2012, October 31). Targeting PD-1: Immune checkpoint strategy finds new spot to arrest cancer. Retrieved from http://www.onclive.com/publications/Oncology-live/2012/October-2012/Targeting-PD-1-Immune-Checkpoint-Strategy-Finds-New-Spot-to-Arrest-Cance
16. McCarthy, E.F. (2006). The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthopaedic Journal, 26, 154–158
17. Mendes, E. (2014, June 16). Immunotherapy: Disrupting the cancer treatment world. Retrieved from http://www.cancer.org/research/acsresearchupdates/more/immunotherapy-disrupting-the-cancer-treatment-world
18. Merck and Co., Inc. (2015). Keytruda® (pembrolizumab) [Package insert]. Retrieved from http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf
19. Murphy, K. (2014). Janeway’s immunobiology (8th ed.). Abingdon, UK: Garland Science.
20. Oxnard, G.R., Morris, M.J., Hodi, F.S., Baker, L.H., Kris, M.G., Venook, A.P., & Schwartz, L.H. (2012). When progressive disease does not mean treatment failure: Reconsidering the criteria for progression. Journal of the National Cancer Institute, 104, 1534–1541. doi:10.1093/jnci/djs353
21. Pazdur, R. (2013, July 3). FDA approval for ipilimumab. Retrieved from http://www.cancer.gov/about-cancer/treatment/drugs/fda-ipilimumab
22. Polovich, M., Olsen, M., & LeFebvre, K. (2014). Chemotherapy and biotherapy guidelines and recommendations for practice (4th ed.). Pittsburgh, PA: Oncology Nursing Society.
23. Postma, T., & Heimans, J.J. (2000). Grading of chemotherapyinduced peripheral neuropathy. Annals of Oncology, 11, 509–513.
24. Postow, M., & Wolchok, J. (2016). Toxicities associated with checkpoint inhibitor immunotherapy. Retrieved from http://www.uptodate.com/contents/toxicities-associated-with -checkpoint-inhibitor-immunotherapy?
25. Prendergast, G.C. (2008). Immune escape as a fundamental trait of cancer: Focus on IDO. Oncogene, 27, 3889–3900.
26. Schadendorf, D., Hodi, F.S., Robert, C., Weber, J.S., Margolin, K., Hamid, O., … Wolchok, J.D. (2015). Pooled analysis of long-term survival data from phase II and phase III trials of Ipilimumab in unresectable or metastatic melanoma. Journal of Clinical Oncology, 33, 1889–1894. doi:10.1200/JCO.2014.56.2736
27. Tarhini, A. (2013). Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: The underlying mechanisms and clinical management. Scientifica, 2013, 857519. doi:10.1155/2013/857519
28. U.S. Food and Drug Administration. (2016). Hematology/oncology (cancer) approvals and safety notifications. Retrieved from http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm
29. U.S. National Library of Medicine. (2016). Severity grading in drug induced liver injury. Retrieved from http://livertox.nih.gov/Severity.html
30. Vajdic, C.M., & van Leeuwen, M.T. (2009). Cancer incidence and risk factors after solid organ transplantation. International Journal of Cancer, 125, 1747–1754.
31. Weber, J.S., Kähler, K., & Hauschild, A. (2012). Management of immune-related adverse events and kinetics of response with ipilimumab. Journal of Clinical Oncology, 30, 2691–2697.